Fc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission.
CRF01_AE HIV
Thailand
antibody dependent cellular cytotoxicity
neonatal Fc receptor
passive immunity
pregnancy
protective immunity
vertical transmission
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
09
2022
accepted:
18
11
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Infants acquire maternal antibodies by Fc receptor transcytosis across the placenta during pregnancy. Fc receptors are expressed on immune cells and are important for activation of effector cell functions. In this study, we evaluated Fc receptor engagement and ADCC activity of plasma binding antibodies from human immunodeficiency virus-1 (HIV) -infected mothers and to identify factors that may contribute to protection from HIV vertical transmission. HIV-specific binding and Fc receptor engagement of plasma antibodies varied between mothers by transmission status and infants by infection status. Non-transmitting (NT) mothers and HIV-uninfected infants had antibodies with higher neonatal Fc receptor (FcRn) and FcγR engagement, as compared to transmitting (T) mothers and HIV+ infants, respectively. A significant inverse correlation between plasma antibody FcRn and FcγR engagement was observed for T mothers, but not NT mothers. Conversely, a significant direct correlation was observed between plasma antibody FcRn and FcγR engagement for HIV- infants, but not for HIV+ infants. Consequently, we observed significantly higher plasma antibody ADCC potency and breadth in HIV- infants, as compared to HIV+ infants. However, no differences in overall ADCC potency and breadth were observed between mothers. FcRn-engagement of HIV-specific antibodies in both mothers and infants predicted a lack of vertical transmission of HIV. This study indicates that HIV-uninfected infants acquire HIV-specific antibodies with greater Fc receptor engagement and thus, greater ADCC capacity.
Identifiants
pubmed: 36578481
doi: 10.3389/fimmu.2022.1051501
pmc: PMC9791209
doi:
Substances chimiques
Receptors, IgG
0
HIV Antibodies
0
Receptors, Fc
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051501Subventions
Organisme : NIAID NIH HHS
ID : R01 AI102725
Pays : United States
Informations de copyright
Copyright © 2022 Barrows, Krebs, Jian, Zemil, Slike, Dussupt, Tran, Mendez-Rivera, Chang, O’Sullivan, Mann, Sanders-Buell, Shubin, Creegan, Paquin-Proulx, Ehrenberg, Laurence-Chenine, Srithanaviboonchai, Thomas, Eller, Ferrari, Robb, Rao, Tovanabutra, Polonis and Wieczorek.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Dev Immunol. 2012;2012:985646
pubmed: 22235228
Sci Transl Med. 2015 Oct 21;7(310):310rv7
pubmed: 26491081
Front Immunol. 2021 Mar 03;12:614246
pubmed: 33746958
J Infect Dis. 1996 May;173(5):1077-84
pubmed: 8627057
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):163-6
pubmed: 23774880
Genome Res. 2017 Mar;27(3):349-361
pubmed: 28174237
PLoS One. 2015 Aug 19;10(8):e0135124
pubmed: 26287814
Health Syst Reform. 2020;6(1):1-7
pubmed: 31567056
Virology. 2020 Sep;548:152-159
pubmed: 32838936
J Virol. 2012 Nov;86(21):11521-32
pubmed: 22896626
J Infect Dis. 2014 Dec 15;210 Suppl 3:S631-40
pubmed: 25414417
J Leukoc Biol. 2009 Jan;85(1):88-97
pubmed: 18820174
PLoS Pathog. 2020 Dec 8;16(12):e1009101
pubmed: 33290394
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
Curr Opin HIV AIDS. 2020 Sep;15(5):282-289
pubmed: 32675573
AIDS Res Hum Retroviruses. 2010 Sep;26(9):967-75
pubmed: 20718630
Cell Host Microbe. 2021 Apr 14;29(4):564-578.e9
pubmed: 33662277
AIDS. 2007 May 11;21(8):1050-3
pubmed: 17457103
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e1-e7
pubmed: 28961680
Front Immunol. 2019 Dec 18;10:2968
pubmed: 31921207
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Virology. 2010 Dec 5;408(1):1-13
pubmed: 20863545
J Immunol Methods. 2017 Apr;443:33-44
pubmed: 28163018
Can J Infect Dis Med Microbiol. 2014 Mar;25(2):75-7
pubmed: 24855474
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Cell. 2019 Jun 27;178(1):202-215.e14
pubmed: 31204102
Cell Host Microbe. 2015 Apr 8;17(4):500-6
pubmed: 25856755
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Adv Virus Res. 2018;100:19-40
pubmed: 29551137
Vaccine. 2003 Jul 28;21(24):3365-9
pubmed: 12850341
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785
BMC Pediatr. 2020 Apr 23;20(1):181
pubmed: 32326903
PLoS Pathog. 2016 Jan 08;12(1):e1005315
pubmed: 26745376
Cell Rep Med. 2021 Apr 20;2(4):100254
pubmed: 33948582
Cell Rep Med. 2021 Oct 19;2(10):100412
pubmed: 34755132
Clin Exp Immunol. 1993 Jul;93(1):56-64
pubmed: 8324904
PLoS Pathog. 2017 Sep 14;13(9):e1006620
pubmed: 28910384
J Immunol Methods. 2012 Dec 14;386(1-2):117-23
pubmed: 23023091
J Obstet Gynaecol Can. 2014 Aug;36(8):721-734
pubmed: 25222168
Virology. 1995 Oct 20;213(1):80-6
pubmed: 7483282
Cell. 2019 Jun 27;178(1):190-201.e11
pubmed: 31204101
Front Immunol. 2019 Dec 11;10:2875
pubmed: 31921139
PLoS One. 2013 Nov 29;8(11):e76104
pubmed: 24312165
PLoS One. 2017 Jul 5;12(7):e0180720
pubmed: 28678869
Front Immunol. 2012 Dec 31;3:399
pubmed: 23293640